Identification

Name
Lurasidone
Accession Number
DB08815
Type
Small Molecule
Groups
Approved
Description

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)

Structure
Thumb
Synonyms
  • Lurasidona
  • Lurasidonum
External IDs
SM-13496
Product Ingredients
IngredientUNIICASInChI Key
Lurasidone HydrochlorideO0P4I5851I367514-88-3NEKCRUIRPWNMLK-SCIYSFAVSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LatudaTablet, film coated40 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
LatudaTablet, film coated60 mg/1OralSunovion2013-07-12Not applicableUs63402 0306 30 nlmimage10 2d3d16f8
LatudaTablet120 mgOralSunovion2012-09-06Not applicableCanada
LatudaTablet, film coated20 mg/1OralSunovion2011-12-07Not applicableUs63402 0302 30 nlmimage10 113d88fc
LatudaTablet40 mgOralSunovion2012-09-06Not applicableCanada
LatudaTablet, film coated80 mg/1OralSunovion2010-10-28Not applicableUs63402 0308 30 nlmimage10 253d12d8
LatudaTablet60 mgOralSunovion2014-03-14Not applicableCanada
LatudaTablet, film coated40 mg/1OralSunovion2010-10-28Not applicableUs63402 0304 30 nlmimage10 2c3e1650
LatudaTablet, film coated120 mg/1OralSunovion2012-04-26Not applicableUs
LatudaTablet80 mgOralSunovion2012-09-05Not applicableCanada
Categories
UNII
22IC88528T
CAS number
367514-87-2
Weight
Average: 492.676
Monoisotopic: 492.255897106
Chemical Formula
C28H36N4O2S
InChI Key
PQXKDMSYBGKCJA-CVTJIBDQSA-N
InChI
InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
IUPAC Name
(1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione
SMILES
O=C1[[email protected]]2[[email protected]@H]3CC[[email protected]@H](C3)[[email protected]]2C(=O)N1C[[email protected]@H]1CCCC[[email protected]]1CN1CCN(CC1)C1=NSC2=CC=CC=C12

Pharmacology

Indication

Treatment of schizophrenia.

Structured Indications
Pharmacodynamics

Lurasidone is a benzothiazol derivative that is an antagonist and binds with high affinity to Dopamine-2 (D2) (Ki = 0.994 nM), 5-HT2A (Ki = 0.47 nM) receptors, and 5-HT7 receptors (Ki = 0.495 nM). It also binds with moderate affinity to alpha-2C adrenergic receptors (Ki = 10.8 nM) and is a partial agonist at 5-HT1A receptors (Ki = 6.38 nM). Its actions on histaminergic and muscarinic receptors are negligible.

Mechanism of action

Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptorNot AvailableHuman
Absorption

Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content.
Bioavailability = 9-19%.

Volume of distribution

6173 L

Protein binding

~99% bound to serum proteins.

Metabolism

Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.

Route of elimination

Urine (~9%) and feces (~80%)

Half life

40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours

Clearance

3902 mL/min

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lurasidone.Investigational
2,5-Dimethoxy-4-ethylamphetamineLurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineLurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with 7-Nitroindazole.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone.Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lurasidone.Experimental
AlaproclateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lurasidone.Approved, Illicit
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Lurasidone.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone.Approved
AmiodaroneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide.Experimental
AmphetamineLurasidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.Approved, Investigational
AprepitantThe serum concentration of Lurasidone can be increased when it is combined with Aprepitant.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone.Approved
AtazanavirThe serum concentration of Lurasidone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Lurasidone can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Azaperone.Vet Approved
AzelastineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lurasidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Barbital.Illicit
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lurasidone.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Benzocaine.Approved
BenzphetamineLurasidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lurasidone is combined with Benzyl alcohol.Approved
BoceprevirThe serum concentration of Lurasidone can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Lurasidone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Lurasidone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lurasidone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lurasidone.Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Bupivacaine.Approved, Investigational
BuprenorphineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Lurasidone is combined with Canertinib.Investigational
CarbamazepineThe serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Lurasidone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone.Experimental
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lurasidone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.Approved
ChlorphentermineLurasidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Lurasidone.Approved
ClarithromycinThe serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Lurasidone can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Lurasidone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone.Approved
CobicistatThe serum concentration of Lurasidone can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.Approved, Illicit
CrizotinibThe serum concentration of Lurasidone can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.Approved
CyclosporineThe serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Lurasidone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lurasidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Lurasidone can be increased when it is combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lurasidone.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lurasidone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineLurasidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Lurasidone is combined with Diethyl ether.Experimental
DiethylpropionLurasidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lurasidone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lurasidone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lurasidone.Experimental
DihydroergotamineThe serum concentration of Lurasidone can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Lurasidone can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.Approved, Illicit
DisopyramideLurasidone may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dixyrazine.Experimental
DopamineDopamine may increase the hypotensive activities of Lurasidone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Lurasidone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lurasidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Illicit
DronedaroneThe serum concentration of Lurasidone can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Lurasidone is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone.Approved, Investigational
EpinephrineEpinephrine may increase the hypotensive activities of Lurasidone.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone.Approved
ErythromycinThe serum concentration of Lurasidone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lurasidone.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone.Approved
EthanolLurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etorphine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Lurasidone can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Lurasidone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Lurasidone.Approved
FluvoxamineThe serum concentration of Lurasidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Lurasidone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone.Approved, Investigational
Fusidic AcidThe serum concentration of Lurasidone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Lurasidone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lurasidone.Approved, Illicit
GepefrineLurasidone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Lurasidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lurasidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Hexobarbital.Approved
HydrocodoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.Approved, Illicit
HydroxyamphetamineLurasidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
IdelalisibThe serum concentration of Lurasidone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.Approved
ImatinibThe serum concentration of Lurasidone can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Lurasidone can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indiplon.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lurasidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lurasidone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Lurasidone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone.Approved
Iofetamine I-123Lurasidone may decrease the stimulatory activities of Iofetamine I-123.Approved
IsavuconazoniumThe serum concentration of Lurasidone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lurasidone.Approved, Vet Approved
IsradipineThe serum concentration of Lurasidone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Lurasidone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lurasidone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Lurasidone can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Lurasidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lurasidone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone.Approved
LisdexamfetamineLurasidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Lurasidone.Approved
LithiumLithium may increase the neurotoxic activities of Lurasidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Lurasidone can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lormetazepam.Approved
LovastatinThe serum concentration of Lurasidone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.Approved
LuliconazoleThe serum concentration of Lurasidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lurasidone can be decreased when it is combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lurasidone.Illicit, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Lurasidone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Lurasidone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Melperone.Approved
MephedroneLurasidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineLurasidone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Meptazinol.Experimental
MequitazineLurasidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Lurasidone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineLurasidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone.Approved
MethotrimeprazineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineLurasidone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lurasidone.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Lurasidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.Approved, Investigational
MetyrosineLurasidone may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Lurasidone.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.Approved, Illicit
MidomafetamineLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MifepristoneThe serum concentration of Lurasidone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lurasidone.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Lurasidone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Investigational
MirtazapineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lurasidone.Approved, Investigational
MMDALurasidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone.Approved, Investigational
NefazodoneThe serum concentration of Lurasidone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lurasidone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Lurasidone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Lurasidone can be increased when it is combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Lurasidone.Approved
NilotinibThe serum concentration of Lurasidone can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lurasidone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone.Approved, Investigational
OlaparibThe serum concentration of Lurasidone can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Opium.Approved, Illicit
OrphenadrineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Lurasidone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Lurasidone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Lurasidone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Lurasidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.Approved
ParaldehydeLurasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Lurasidone.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.Approved, Vet Approved
PentobarbitalThe serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perazine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Lurasidone.Approved, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Lurasidone.Approved, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenibut.Experimental
PhenobarbitalThe serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoxyethanol.Approved
PhentermineLurasidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Lurasidone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Lurasidone.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Lurasidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Lurasidone.Approved
PizotifenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Lurasidone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleLurasidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Lurasidone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lurasidone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Prilocaine.Approved
PrimidoneThe serum concentration of Lurasidone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideLurasidone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Lurasidone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Lurasidone is combined with PSD502.Investigational
PseudoephedrineLurasidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Lurasidone.Approved
QuinidineLurasidone may increase the QTc-prolonging activities of Quinidine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Lurasidone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.Approved
RifabutinThe serum concentration of Lurasidone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Lurasidone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Lurasidone can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ritanserin.Investigational
RitobegronLurasidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Lurasidone can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Romifidine.Vet Approved
RopiniroleLurasidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Lurasidone.Approved
RotigotineLurasidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone.Approved
SaquinavirThe serum concentration of Lurasidone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Lurasidone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.Approved, Vet Approved
SildenafilThe serum concentration of Lurasidone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Lurasidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lurasidone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lurasidone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lurasidone.Investigational
St. John's WortThe serum concentration of Lurasidone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Lurasidone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.Approved, Investigational
SulfisoxazoleThe serum concentration of Lurasidone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone.Approved, Investigational
SuvorexantLurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone.Approved
TelaprevirThe serum concentration of Lurasidone can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Lurasidone can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Lurasidone.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrodotoxin.Investigational
ThalidomideLurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride.Approved, Investigational
TiclopidineThe serum concentration of Lurasidone can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Lurasidone.Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Lurasidone.Experimental
Valproic AcidThe risk or severity of adverse effects can be increased when Lurasidone is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe serum concentration of Lurasidone can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Veralipride.Experimental
VerapamilThe serum concentration of Lurasidone can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Lurasidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lurasidone.Approved, Investigational
VoriconazoleThe serum concentration of Lurasidone can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone.Approved, Investigational
ZolpidemLurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lurasidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.Approved, Investigational
Food Interactions
  • When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours.

References

General References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
  2. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428]
External Links
KEGG Drug
D04820
PubChem Compound
213046
PubChem Substance
175427100
ChemSpider
184739
BindingDB
85222
ChEBI
70735
ChEMBL
CHEMBL1237021
PharmGKB
PA166129557
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lurasidone
ATC Codes
N05AE05 — Lurasidone
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (452 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableMale, Healthy Normal Subjects1
1CompletedNot AvailableMetabolism / Pharmacokinetics1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableSchizophrenia Patients1
1CompletedNot AvailableSchizophrenic Disorders3
1CompletedBasic ScienceSchizophrenic Disorders1
1CompletedTreatmentAutism, Early Infantile / Schizophrenic Disorders1
2CompletedTreatmentAffective Disorders / Asperger's Syndrome / Autistic Disorder / Bipolar I Disorder / Bipolar II Disorder / Child Development Disorders, Pervasive / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder / Severe Major Depression With Psychotic Features / Severe Mood Disorder With Psychotic Features / Single Episode Major Depression Without Psychotic Symptoms1
2CompletedTreatmentSchizophrenic Disorders4
2, 3Not Yet RecruitingTreatmentDepression, Bipolar / Suicidal Ideas / Suicidal Ideation / Suicide, Attempted1
3Active Not RecruitingTreatmentAutism, Early Infantile / Depression, Bipolar / Schizophrenic Disorders1
3Active Not RecruitingTreatmentBipolar I Disorder1
3Active Not RecruitingTreatmentDepression, Bipolar1
3CompletedTreatmentAutism, Early Infantile1
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar I Disorder3
3CompletedTreatmentDepression, Bipolar5
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentMajor Depressive Disorder With Mixed Features1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentSchizophrenic Disorders10
3RecruitingTreatmentBipolar Disorder (BD)1
3WithdrawnTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
4RecruitingTreatmentSchizophrenic Disorders2
4SuspendedTreatmentBipolar Disorder (BD) / Bipolar I / Bipolar II / Bipolar Spectrum Disorder / Mania1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableUnknown StatusNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusTreatmentDepression, Bipolar1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral120 mg
TabletOral20 mg
TabletOral40 mg
TabletOral60 mg
TabletOral80 mg
Tablet, film coatedOral120 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral60 mg/1
Tablet, film coatedOral80 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9174975Yes2006-12-252026-12-25Us
US9259423Yes2011-11-232031-11-23Us
US8729085Yes2006-11-262026-11-26Us
US5532372Yes1999-01-022019-01-02Us
US8883794Yes2006-11-262026-11-26Us
USRE45573Yes2005-12-232025-12-23Us
US9555027No2006-05-262026-05-26Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00789 mg/mLALOGPS
logP5.25ALOGPS
logP4.56ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.75 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity139.33 m3·mol-1ChemAxon
Polarizability56.2 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9907
Caco-2 permeable+0.5257
P-glycoprotein substrateSubstrate0.6029
P-glycoprotein inhibitor IInhibitor0.6713
P-glycoprotein inhibitor IIInhibitor0.73
Renal organic cation transporterInhibitor0.5487
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5922
CYP450 1A2 substrateNon-inhibitor0.677
CYP450 2C9 inhibitorInhibitor0.6714
CYP450 2D6 inhibitorNon-inhibitor0.8292
CYP450 2C19 inhibitorInhibitor0.7439
CYP450 3A4 inhibitorNon-inhibitor0.7835
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8126
Ames testNon AMES toxic0.6477
CarcinogenicityNon-carcinogens0.8986
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.4051 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6636
hERG inhibition (predictor II)Inhibitor0.5858
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Aromatic monoterpenoids / Isoindolones / Benzothiazoles / Dialkylarylamines / N-alkylpiperazines / Aminothiazoles / Benzenoids / Pyrrolidine-2-ones / Imidolactams / N-substituted carboxylic acid imides
show 11 more
Substituents
N-arylpiperazine / Aromatic monoterpenoid / Monoterpenoid / Norbornane monoterpenoid / Isoindolone / 1,2-benzothiazole / Isoindoline / Isoindole or derivatives / Dialkylarylamine / N-alkylpiperazine
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, dicarboximide, bridged compound, 1,2-benzisothiazole (CHEBI:70735)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Drug created on July 24, 2011 11:04 / Updated on October 21, 2017 09:34